Evaluation of the stability of (99m)Tc-ECD and stabilized (99m)Tc-HMPAO stored in syringes.
OBJECTIVE
To determine and compare the stability of (99m)Tc-ECD and stabilized (99m)Tc-HMPAO when stored in syringes over an 8-h period.


METHODS
(99m)Tc-ECD and stabilized (99m)Tc-HMPAO were prepared according to the manufacturers' protocols, with the following exception: eluate less than 60 min old was used to prepare (99m)Tc-HMPAO rather than the recommended 30 min. Once prepared, 185 MBq (5 mCi) of both products were drawn into 5-mL syringes and allowed to sit at room temperature. At 2, 4, 6, and 8 h after preparation, the radiochemical purity (RCP) of the contents of the syringes was determined and compared to the RCP of the products in vials. Retention of activity of each product in syringes was also evaluated by measuring activity remaining in each syringe (and filter, in the case of (99m)Tc-HMPAO) after expressing its contents.


RESULTS
The RCP of stabilized (99m)Tc-HMPAO stored in syringes decreased from a mean of 87.7% at 2 h to 74.0% at 8 h after preparation. In contrast, (99m)Tc-ECD retained an RCP of greater than 94% throughout the time tested. The impurity that appeared to increase over time with (99m)Tc-HMPAO was found to be sodium pertechnetate. Total retention of activity remaining in the syringe and filter ranged from 11.6% at 2 h to 9.5% at 8 h for (99m)Tc-HMPAO; the syringe itself retained less than 5% of the total activity at all time periods. (99m)Tc-ECD exhibited 6.2% to 11.3% retention of activity in the syringe. The sorption of sodium pertechnetate to the syringe for the same time period was less than 1%.


CONCLUSIONS
(99m)Tc-ECD is a more stable product than stabilized (99m)Tc-HMPAO in a syringe. Both products demonstrate retention of radioactivity in the syringe. Some of this retention may denote sorption of the products to plastic.
Koslowsky
I L
IL
Nuclear Medicine, Foothills Medical Centre, Calgary, Alberta, Canada. ingrid.koslowaky@CalgaryHealthRegion.ca
Brake
S E
SE
Bitner
S J
SJ
D003545:Cysteine / Q000031:analogs & derivatives* / Q000737:chemistry*; D004355:Drug Stability; D004356:Drug Storage; D015609:Organotechnetium Compounds / Q000737:chemistry*; D010091:Oximes / Q000737:chemistry*; D019275:Radiopharmaceuticals / Q000737:chemistry*; D013594:Syringes; D019690:Technetium Tc 99m Exametazime
D015609:Organotechnetium Compounds; D010091:Oximes; D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime; C059659:technetium Tc 99m bicisate; D003545:Cysteine